5 Mistakes I Made When I Started A GLP-1
Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid.
Here’s How Eli Lilly’s Oncology Drugs Are Poised Ahead of Q3 Earnings
While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for obesity), the company also generates a meaningful portion of revenues from its oncology franchise. Sales from the oncology drugs accounted for more than 15% of Lilly’s first-half 2025 revenues, which grew about 10% year […]
A New Chapter in Diabetes and Obesity Care: Local Access to Advanced GLP-1 and GIP RA Therapies
Pakistan’s healthcare landscape has entered a pivotal phase in the management of diabetes and obesity. For years, advanced incretin-based therapies, known globally for their role in blood sugar and weight control, remained out of reach for most local patients due to high import costs and limited supply. That gap is now beginning to close. What […]
Opinion: Trump’s $150-per-month GLP-1 plan won’t reach people like me
On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling. For patients who’ve been priced out, that […]
STAT+: Can ‘food noise’ be measured? Telehealth giant Ro rolls out a new scale for obesity care
Telehealth companies that have seized on the boom in weight loss drugs are playing a bigger role not just in treating patients with obesity, but also shaping how the medical mainstream understands obesity. A dominant player in the field, Ro, said Friday it has launched a new questionnaire designed to measure “food noise,” a term […]
GLP-1s May Protect Against AMD in Those Without Diabetes
People without diabetes who receive GLP-1 receptor agonists for the treatment of overweight or obesity face a reduced risk of developing dry age-related macular degeneration, a recent study shows. Medscape Medical News
Obesity drugs regulate neural systems to curb appetite, research reveals
A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management drugs semaglutide and tirzepatide that help suppress appetite, according to findings published in The Journal of Clinical Investigation.
GLP-1 prescription rate relatively flat: Study
GLP-1 prescribing in the US may have reached a plateau, new data suggests. Prescribing rates remained stable from June to September, according to an analysis of EHR data from researchers at Truveta — a platform that includes de-identified patient data from more than 900 hospitals to support medical research advancements. In June, the overall prescribing […]
Weight loss drugs: Semaglutide boosts heart health regardless of how much weight patients lose, study suggests
The cardiovascular benefits of weight loss drug semaglutide (Ozempic, Wegovy) occur regardless of how much weight a person loses or their starting body weight, new analysis suggests.1Study authors said the findings indicate many more people could benefit from taking the glucagon-like peptide-1 (GLP-1) receptor agonist and current restrictions based on body mass index (BMI) thresholds […]
New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease
Individuals with metabolic syndrome are at an increased risk of developing chronic kidney disease (CKD) or accelerating the progression of pre-existing CKD. Further, such individuals are predisposed to developing diabetes mellitus, increasing their susceptibility to diabetic kidney disease (DKD). Current DKD treatments have expanded to include renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal […]